Santilli F, Spagnoli A, Mohn A, Tumini S, Verrotti A, Cipollone F, Mezzetti A, Chiarelli F
Department of Medicine, Division of Pediatrics, University of Chieti, 66100 Chieti, Italy.
J Clin Endocrinol Metab. 2001 Aug;86(8):3871-6. doi: 10.1210/jcem.86.8.7752.
This study was designed to evaluate whether vascular endothelial growth factor serum concentrations may identify adolescents with onset of type 1 diabetes during childhood at greater risk to develop persistent microalbuminuria and incipient diabetic nephropathy. In January 1989, vascular endothelial growth factor serum levels were measured in 101 normoalbuminuric diabetic children and adolescents (aged 7-14.9 yr; onset of diabetes before age 18 yr; duration of diabetes >7 yr). Participants were clinically examined at baseline and annually thereafter. Vascular endothelial growth factor serum concentrations were measured every year during the 8-yr follow-up period. Over 8 yr, 11 of 101 patients (10.9%) developed persistent microalbuminuria; no patient developed overt nephropathy. The risk of developing microalbuminuria was higher in children with increased vascular endothelial growth factor serum levels (using 160 pg/ml as the arbitrary cut-off point; group 1) compared with those with normal vascular endothelial growth factor serum levels at the beginning of the study (group 2; 19.2 vs. 2.0%; P < 0.01; sensitivity, 90.9%; specificity, 53.3%). The odds ratio for the occurrence of microalbuminuria after adjustment for confounding variables (albumin excretion rate, sex, hemoglobin A(1c), mean blood pressure, cholesterol, and triglycerides) in type 1 diabetic adolescents with elevated vascular endothelial growth factor serum levels was 4.1 (95% confidence interval, 2.0-10.9). These results suggest that vascular endothelial growth factor serum concentrations may be one of the predictors and risk factors for microalbuminuria and incipient diabetic nephropathy in adolescents and young adults with onset of diabetes during childhood. Persistently increased vascular endothelial growth factor serum levels may help to identify normotensive, normoalbuminuric patients with type 1 diabetes who are predisposed to develop persistent microalbuminuria later in life.
本研究旨在评估血清血管内皮生长因子浓度是否可识别出在儿童期发病的1型糖尿病青少年,这些青少年发生持续性微量白蛋白尿和早期糖尿病肾病的风险更高。1989年1月,对101名正常白蛋白尿的糖尿病儿童和青少年(年龄7 - 14.9岁;糖尿病发病年龄在18岁之前;糖尿病病程>7年)测量了血清血管内皮生长因子水平。参与者在基线时进行了临床检查,此后每年检查一次。在8年的随访期内每年测量血清血管内皮生长因子浓度。8年间,101例患者中有11例(10.9%)发生了持续性微量白蛋白尿;无患者发生显性肾病。与研究开始时血清血管内皮生长因子水平正常的儿童(第2组)相比,血清血管内皮生长因子水平升高的儿童(以160 pg/ml作为任意切点;第1组)发生微量白蛋白尿的风险更高(19.2%对2.0%;P<0.01;敏感性为90.9%;特异性为53.3%)。在调整了混杂变量(白蛋白排泄率、性别、糖化血红蛋白A1c、平均血压、胆固醇和甘油三酯)后,血清血管内皮生长因子水平升高的1型糖尿病青少年发生微量白蛋白尿的比值比为4.1(95%置信区间,2.0 - 10.9)。这些结果表明,血清血管内皮生长因子浓度可能是儿童期发病的青少年和年轻成人微量白蛋白尿和早期糖尿病肾病的预测指标和危险因素之一。血清血管内皮生长因子水平持续升高可能有助于识别出1型糖尿病血压正常、白蛋白尿正常但日后易发生持续性微量白蛋白尿的患者。